Background: Measurement of red blood cell thiopurine S-methyl transferase (TPMT) enzyme activity before commencing thiopurine therapy is recommended to avoid severe bone marrow suppression in TPMT-deficient patients. Patient's samples go through preanalytical transportation and storage steps before measurement. We studied patient's TPMT activity sample data to assess the effect of preanalytical variables including transportation time.
Methods: A total of 8524 TPMT enzyme activity analyses were conducted from 2002 to 2010 in a single laboratory, with samples sent from seven centres throughout New Zealand. TPMT activity was correlated with time of arrival at the reference laboratory, patient gender and age and centre of sample collection.
Results: The 6348 (74%) selected TPMT measurements that fulfilled selection criteria ranged from 0 to 25.8 IU/mL. Median delay to sample analysis was 42 h. Median TPMT activity was significantly lower for all centres compared with the reference centre (P < 0.001). Delay in sample arrival was significantly and independently correlated with TPMT enzyme activity (ANCOVA; P < 0.001), which showed a 0.011 (95% CI, 0.008-0.014) IU/mL decrease per extra hour of delay. After correcting for these data, one centre still had a significantly lower TPMT enzyme activity compared with the reference centre.
Conclusions: There was a significant negative correlation between TPMT enzyme activity and delay from sample collection to analysis. Transportation time is therefore an important preanalytical variable influencing TPMT activity. Samples from one centre had a lower TPMT activity after correcting for transportation delay, suggesting that other factors related to sample processing may also be relevant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0004563212474558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of azathioprine in patients with Cronkhite-Canada syndrome: a case series from Peking Union Medical College Hospital.
BMC Pharmacol Toxicol
December 2024
Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
Background: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary chronic inflammatory disease characteristic of gastrointestinal polyps and ectodermal abnormalities. Corticosteroid therapy is the mainstay medication for CCS. Few studies indicated immunosuppressants might be the choices for patients with steroid refractory, steroid dependent or intolerant.
View Article and Find Full Text PDFUtilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data-linkage study.
Pharmacotherapy
January 2025
The University of Sydney School of Pharmacy, Camperdown, New South Wales, Australia.
Introduction: Thiopurine drugs are metabolized by thiopurine methyltransferase (TPMT) and low TPMT activity can result in severe adverse drug reactions. Therefore, TPMT testing is recommended for individuals receiving thiopurines to reduce the risk of toxicity.
Objectives: The objectives of this study were to assess the rate of TPMT testing among individuals receiving thiopurines and explore factors associated with undergoing TPMT testing in Australia.
Genetic association analysis and frequency of NUDT15*3 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease in a large Dutch cohort.
Pharmacogenomics J
November 2024
Department of Clinical Chemistry, Catharina Hospital, Eindhoven, the Netherlands.
Article Synopsis
- Thiopurine drugs are crucial for managing inflammatory bowel disease (IBD), but they can cause side effects, particularly thiopurine-induced myelosuppression (TIM).
- A study in the Netherlands explored the frequency of the NUDT15*3 genetic polymorphism and its connection to TIM in IBD patients.
- Out of 988 patients, 1.3% had the NUDT15*3 variant; among those on thiopurines, 50% of carriers developed TIM compared to just 2.3% of non-carriers, indicating the importance of genetic testing before treatment.
Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients.
Pharmacogenet Genomics
February 2025
Division of Neonatology, Department of Pediatrics, Fetal and Neonatal Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Background: Pharmacogenomic testing identifies gene polymorphisms impacting drug metabolism, aiding in optimizing treatment efficacy and minimizing toxicity, thus potentially reducing healthcare utilization. 6-Mercaptopurine metabolism is affected by thiopurine methyltransferase ( TPMT ) and nudix hydrolase 15 ( NUDT15 ) polymorphisms. We sought to estimate the budget impact of preemptive pharmacogenomic testing for these genes in pediatric acute lymphoblastic leukemia (ALL) patients from an institutional perspective.
View Article and Find Full Text PDFGenetic profiling of in the Slovenian population.
Pharmacogenomics
November 2024
University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, Ljubljana, 1000, Slovenia.
Article Synopsis
- This text discusses the use of pharmacogenomics to tailor thiopurine therapy based on genetic variants, initially focusing on its success in Asian populations but now recognized in European populations as well.
- Researchers sequenced specific gene regions in Slovenian individuals to evaluate the pharmacogenetic role of variants related to thiopurine therapy for patients with acute lymphoblastic leukemia (ALL).
- The study found several genetic variants, including one with known clinical relevance, but most variants were not linked to the dosage of thiopurines in ALL patients, suggesting the need for deeper studies in larger groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!